Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
80°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx Inc
(NQ:
ARDX
)
6.350
+0.300 (+4.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ardelyx Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 01, 2024
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
3 mid-caps under $20 that Wall Street loves
January 23, 2024
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Ardelyx, Inc. Reports Employment Inducement Grants
January 12, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 8/30
August 30, 2023
Via
Investor Brand Network
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
January 08, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
January 03, 2024
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
December 20, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
November 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Departure of Board Member
November 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Participate at the Jefferies London Healthcare Conference
November 10, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
November 06, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
November 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
October 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
October 30, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
October 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
October 18, 2023
Conference call scheduled for 8:00 a.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is One of Wednesday Morning’s Most Active Stocks
October 18, 2023
Via
Investor Brand Network
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
October 17, 2023
Additional non-dilutive capital extends runway to support the launch of XPHOZAH® (tenapanor) and continued commercial investment into IBSRELA® (tenapanor) in the U.S.
From
Ardelyx, Inc.
Via
GlobeNewswire
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
October 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
October 04, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
September 28, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tenapanor for Hyperphosphatemia Approved in Japan
September 25, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
September 11, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
September 07, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
August 02, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
July 27, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.